28.9 C
Karachi
Thursday, March 28, 2024
- Advertisement -
 

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy

TOP NEWS

Reuters
Reuters
Reuters is an international news organisation owned by Thomson Reuters

Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

 

View this post on Instagram

 

A post shared by Pfizer Inc. (@pfizerinc)

Related: Pfizer COVID-19 vaccine shows 90.7% efficacy in trial in children 

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.

 

View this post on Instagram

 

A post shared by Pfizer Inc. (@pfizerinc)

- Advertisement -
- Advertisement -
 

POLL

Will the PML-N led govt be able to steer Pakistan out of economic crisis?

- Advertisement -
 

MORE STORIES